| 摘要: |
| 肿瘤相关分子标记物的发现，导致靶向治疗药物迅速发展。我们对近期在非小细胞肺癌中发现的可能影响靶向治疗的相关分子标记物，即所谓的驱动突变基因进行综合分析。期待依据肿瘤个体基因情况而决定的靶向治疗，可使患者在一定程度上获得更大治疗收益。 |
| 关键词: 非小细胞 肺肿瘤 驱动突变基因 |
| DOI：10.3969/j.issn1008-0392.2013.01.027 |
|
| 基金项目:国家自然科学基金(30873023) |
|
| Driver mutations in non-small-cell lung cancer |
| LIU Lu,ZHOU Cai-cun |
| (Dept.of Oncology,Pulmonary Hospital,Tongji University,Shanghai 200433,China) |
| Abstract: |
| The discovery of cancer molecular markers has led to the development of targeted agents. We review current knowledge about molecular markers in non-small-cell lung cancer which may have potential clinical relevance to targeted therapies. The adoption of tailored treatment according to the genetic make-up of individual tumors would involve a paradigm shift, but might lead to substantial therapeutic improvement. |
| Key words: non-small cell lung cancer driver mutation |
